Association of anti-SARS-COV-2 vaccine with increased incidence of myositis-related anti-RNA-synthetases auto-antibodies
Introduction: SARS-CoV-2 is a RNA virus that associates with heterogeneous clinical manifestations and complications. Auto-antibodies are identified in approximately 50% of hospitalized COVID-19 patients. Objectives: To determine the global incidence of myositis-related auto-antibodies (non Jo1-RNA...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-01-01
|
| Series: | Journal of Translational Autoimmunity |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589909022000211 |
| _version_ | 1828165846294331392 |
|---|---|
| author | Laura García-Bravo Myriam Calle-Rubio Miguel Fernández-Arquero Kauzar Mohamed Mohamed Teresa Guerra-Galán María Guzmán-Fulgencio Antonia Rodríguez de la Peña Cristina Cañizares Bárbara López Cristina Vadillo Jorge Matías-Guiu Asunción Nieto Barbero José Luis Álvarez-Sala Walther Silvia Sánchez-Ramón Juliana Ochoa-Grullón |
| author_facet | Laura García-Bravo Myriam Calle-Rubio Miguel Fernández-Arquero Kauzar Mohamed Mohamed Teresa Guerra-Galán María Guzmán-Fulgencio Antonia Rodríguez de la Peña Cristina Cañizares Bárbara López Cristina Vadillo Jorge Matías-Guiu Asunción Nieto Barbero José Luis Álvarez-Sala Walther Silvia Sánchez-Ramón Juliana Ochoa-Grullón |
| author_sort | Laura García-Bravo |
| collection | DOAJ |
| description | Introduction: SARS-CoV-2 is a RNA virus that associates with heterogeneous clinical manifestations and complications. Auto-antibodies are identified in approximately 50% of hospitalized COVID-19 patients. Objectives: To determine the global incidence of myositis-related auto-antibodies (non Jo1-RNA synthetases: anti-PL7, anti-PL12, anti-EJ, anti-OJ and RNA-sensor: anti-MDA5) in our laboratory during COVID-19 pandemics, and to describe the clinical and laboratory features of these patients. Study design: A retrospective study was performed from 2015 to 2021 in a cohort of 444 patients with suspected inflammatory myopathy. The incidence of positive results for the MSA was expressed as absolute value per year for the reference population. Immunoblot analysis, indirect immunofluorescence and HLA typing of 36 patients with positivity for MSAs were collected and analyzed. Results: We observed MSA positive in 28 patients in 2020 and 36 patients in 2021, representing a mean increase of 6-fold respect to previous years since 2015 (range, 0 to 19). In 2020, the most common antibody detected was anti-MDA5 (68%). In contrast, in 2021 the most common antibodies were anti-PL7 and/or anti-PL12 (69%). All patients in 2021 with positive anti-synthetases were fully vaccinated, 4 had previous documented infection, with median time from vaccine to MSA positivity of 5 months. Eight out of 36 patients (22%) reported clinical onset after SARS-CoV-2 vaccination and 6 out of 36 (17%) presented clinical and/or radiological worsening after SARS-CoV-2 vaccination. All patients presented with a known human leukocyte antigen (HLA)-DRB1* allele associated with ASS. The most prevalent alleles identified were DRB1*03:01, DRB1*04, DRB1*11:01, corresponding to 70% (16/23) of our cohort. Conclusions: Our preliminary data show an increased incidence of anti-synthetase antibodies during COVID-19 pandemic and SARS-CoV-2 vaccination associated to HLA DRB1* risk allele. Differential profiles of MSA specificities were observed: mainly against RNA-sensors in 2020 and against RNA-synthetases in 2021. Further studies are needed to support the association between SARS-CoV-2 infection and/or vaccination and the occurrence of this autoimmune syndrome. |
| first_indexed | 2024-04-12T01:50:41Z |
| format | Article |
| id | doaj.art-a38be6c3915249d0a482dc156f3d6bd6 |
| institution | Directory Open Access Journal |
| issn | 2589-9090 |
| language | English |
| last_indexed | 2024-04-12T01:50:41Z |
| publishDate | 2022-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Translational Autoimmunity |
| spelling | doaj.art-a38be6c3915249d0a482dc156f3d6bd62022-12-22T03:52:56ZengElsevierJournal of Translational Autoimmunity2589-90902022-01-015100160Association of anti-SARS-COV-2 vaccine with increased incidence of myositis-related anti-RNA-synthetases auto-antibodiesLaura García-Bravo0Myriam Calle-Rubio1Miguel Fernández-Arquero2Kauzar Mohamed Mohamed3Teresa Guerra-Galán4María Guzmán-Fulgencio5Antonia Rodríguez de la Peña6Cristina Cañizares7Bárbara López8Cristina Vadillo9Jorge Matías-Guiu10Asunción Nieto Barbero11José Luis Álvarez-Sala Walther12Silvia Sánchez-Ramón13Juliana Ochoa-Grullón14Department of Clinical Immunology and IdISSC, Hospital Clínico San Carlos, Madrid, SpainPneumology and IdISSC, Hospital Clínico San Carlos, Madrid, SpainDepartment of Clinical Immunology and IdISSC, Hospital Clínico San Carlos, Madrid, SpainDepartment of Clinical Immunology and IdISSC, Hospital Clínico San Carlos, Madrid, SpainDepartment of Clinical Immunology and IdISSC, Hospital Clínico San Carlos, Madrid, SpainDepartment of Clinical Immunology and IdISSC, Hospital Clínico San Carlos, Madrid, SpainDepartment of Clinical Immunology and IdISSC, Hospital Clínico San Carlos, Madrid, SpainDepartment of Clinical Immunology and IdISSC, Hospital Clínico San Carlos, Madrid, SpainDepartment of Clinical Immunology and IdISSC, Hospital Clínico San Carlos, Madrid, SpainRheumatology, Hospital Clínico San Carlos, Madrid, SpainNeurology, Hospital Clínico San Carlos, Madrid, SpainPneumology and IdISSC, Hospital Clínico San Carlos, Madrid, SpainPneumology and IdISSC, Hospital Clínico San Carlos, Madrid, SpainDepartment of Clinical Immunology and IdISSC, Hospital Clínico San Carlos, Madrid, SpainDepartment of Clinical Immunology and IdISSC, Hospital Clínico San Carlos, Madrid, Spain; Corresponding author. Department of Clinical Immunology Laboratory Medicine Institute, Hospital Clínico San Carlos and IdISSC Calle Profesor Martín Lagos S/N 28040, Madrid, Spain.Introduction: SARS-CoV-2 is a RNA virus that associates with heterogeneous clinical manifestations and complications. Auto-antibodies are identified in approximately 50% of hospitalized COVID-19 patients. Objectives: To determine the global incidence of myositis-related auto-antibodies (non Jo1-RNA synthetases: anti-PL7, anti-PL12, anti-EJ, anti-OJ and RNA-sensor: anti-MDA5) in our laboratory during COVID-19 pandemics, and to describe the clinical and laboratory features of these patients. Study design: A retrospective study was performed from 2015 to 2021 in a cohort of 444 patients with suspected inflammatory myopathy. The incidence of positive results for the MSA was expressed as absolute value per year for the reference population. Immunoblot analysis, indirect immunofluorescence and HLA typing of 36 patients with positivity for MSAs were collected and analyzed. Results: We observed MSA positive in 28 patients in 2020 and 36 patients in 2021, representing a mean increase of 6-fold respect to previous years since 2015 (range, 0 to 19). In 2020, the most common antibody detected was anti-MDA5 (68%). In contrast, in 2021 the most common antibodies were anti-PL7 and/or anti-PL12 (69%). All patients in 2021 with positive anti-synthetases were fully vaccinated, 4 had previous documented infection, with median time from vaccine to MSA positivity of 5 months. Eight out of 36 patients (22%) reported clinical onset after SARS-CoV-2 vaccination and 6 out of 36 (17%) presented clinical and/or radiological worsening after SARS-CoV-2 vaccination. All patients presented with a known human leukocyte antigen (HLA)-DRB1* allele associated with ASS. The most prevalent alleles identified were DRB1*03:01, DRB1*04, DRB1*11:01, corresponding to 70% (16/23) of our cohort. Conclusions: Our preliminary data show an increased incidence of anti-synthetase antibodies during COVID-19 pandemic and SARS-CoV-2 vaccination associated to HLA DRB1* risk allele. Differential profiles of MSA specificities were observed: mainly against RNA-sensors in 2020 and against RNA-synthetases in 2021. Further studies are needed to support the association between SARS-CoV-2 infection and/or vaccination and the occurrence of this autoimmune syndrome.http://www.sciencedirect.com/science/article/pii/S2589909022000211MyositisInterstitial lung diseaseMyositis specific antibodiesCOVID19SARS-CoV-2 vaccines |
| spellingShingle | Laura García-Bravo Myriam Calle-Rubio Miguel Fernández-Arquero Kauzar Mohamed Mohamed Teresa Guerra-Galán María Guzmán-Fulgencio Antonia Rodríguez de la Peña Cristina Cañizares Bárbara López Cristina Vadillo Jorge Matías-Guiu Asunción Nieto Barbero José Luis Álvarez-Sala Walther Silvia Sánchez-Ramón Juliana Ochoa-Grullón Association of anti-SARS-COV-2 vaccine with increased incidence of myositis-related anti-RNA-synthetases auto-antibodies Journal of Translational Autoimmunity Myositis Interstitial lung disease Myositis specific antibodies COVID19 SARS-CoV-2 vaccines |
| title | Association of anti-SARS-COV-2 vaccine with increased incidence of myositis-related anti-RNA-synthetases auto-antibodies |
| title_full | Association of anti-SARS-COV-2 vaccine with increased incidence of myositis-related anti-RNA-synthetases auto-antibodies |
| title_fullStr | Association of anti-SARS-COV-2 vaccine with increased incidence of myositis-related anti-RNA-synthetases auto-antibodies |
| title_full_unstemmed | Association of anti-SARS-COV-2 vaccine with increased incidence of myositis-related anti-RNA-synthetases auto-antibodies |
| title_short | Association of anti-SARS-COV-2 vaccine with increased incidence of myositis-related anti-RNA-synthetases auto-antibodies |
| title_sort | association of anti sars cov 2 vaccine with increased incidence of myositis related anti rna synthetases auto antibodies |
| topic | Myositis Interstitial lung disease Myositis specific antibodies COVID19 SARS-CoV-2 vaccines |
| url | http://www.sciencedirect.com/science/article/pii/S2589909022000211 |
| work_keys_str_mv | AT lauragarciabravo associationofantisarscov2vaccinewithincreasedincidenceofmyositisrelatedantirnasynthetasesautoantibodies AT myriamcallerubio associationofantisarscov2vaccinewithincreasedincidenceofmyositisrelatedantirnasynthetasesautoantibodies AT miguelfernandezarquero associationofantisarscov2vaccinewithincreasedincidenceofmyositisrelatedantirnasynthetasesautoantibodies AT kauzarmohamedmohamed associationofantisarscov2vaccinewithincreasedincidenceofmyositisrelatedantirnasynthetasesautoantibodies AT teresaguerragalan associationofantisarscov2vaccinewithincreasedincidenceofmyositisrelatedantirnasynthetasesautoantibodies AT mariaguzmanfulgencio associationofantisarscov2vaccinewithincreasedincidenceofmyositisrelatedantirnasynthetasesautoantibodies AT antoniarodriguezdelapena associationofantisarscov2vaccinewithincreasedincidenceofmyositisrelatedantirnasynthetasesautoantibodies AT cristinacanizares associationofantisarscov2vaccinewithincreasedincidenceofmyositisrelatedantirnasynthetasesautoantibodies AT barbaralopez associationofantisarscov2vaccinewithincreasedincidenceofmyositisrelatedantirnasynthetasesautoantibodies AT cristinavadillo associationofantisarscov2vaccinewithincreasedincidenceofmyositisrelatedantirnasynthetasesautoantibodies AT jorgematiasguiu associationofantisarscov2vaccinewithincreasedincidenceofmyositisrelatedantirnasynthetasesautoantibodies AT asuncionnietobarbero associationofantisarscov2vaccinewithincreasedincidenceofmyositisrelatedantirnasynthetasesautoantibodies AT joseluisalvarezsalawalther associationofantisarscov2vaccinewithincreasedincidenceofmyositisrelatedantirnasynthetasesautoantibodies AT silviasanchezramon associationofantisarscov2vaccinewithincreasedincidenceofmyositisrelatedantirnasynthetasesautoantibodies AT julianaochoagrullon associationofantisarscov2vaccinewithincreasedincidenceofmyositisrelatedantirnasynthetasesautoantibodies |